drugset / Trial / NCT01515358

A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants

NCT01515358 ↗

Phase 1 Completed 18 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindTreatment

Summary

The purposes of this study are to determine the safety and side effects of LY3000328, to determine how well the body will tolerate LY3000328, and to determine how long LY3000328 remains in the body.

Timeline

Start
2012-02
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3000328 Unknown 300 mg/kg Oral

Indications

No indication recorded.